Data Integrity in Pharmaceutical Manufacturing: ALCOA+ Principles, Regulatory Expectations and Strategies for Effective Data Governance

Abstract

Data integrity is a fundamental component of pharmaceutical quality systems because product quality, patient safety and regulatory decisions depend on reliable and trustworthy data. Digital transformation has expanded the use of computerized systems, laboratory information management systems, electronic batch records, cloud platforms, process analytical technology and artificial intelligence in pharmaceutical development and manufacturing. These technologies improve traceability and efficiency but also create new risks related to unauthorized access, inappropriate data modification, incomplete metadata, inadequate audit trails, system validation and cyber-security. The ALCOA+ framework—Attributable, Legible, Contemporaneous, Original, Accurate, Complete, Consistent, Enduring and Available—provides a practical basis for evaluating data integrity across the data life cycle.

This review synthesizes regulatory guidance and recent literature on data governance, computerized systems, audit trails, Industry 4.0, cloud computing, artificial intelligence and digital pharmaceutical manufacturing. Regulatory expectations from the US Food and Drug Administration (FDA), Medicines and Healthcare products Regulatory Agency (MHRA), World Health Organization (WHO), Pharmaceutical Inspection Co-operation Scheme (PIC/S) and European Union (EU) GMP are compared. Common data integrity observations and corresponding CAPA strategies are also summarized. The review concludes that effective data integrity requires an integrated quality culture supported by risk-based governance, validated computerized systems, access control, audit-trail review, secure archival, personnel training and continuous monitoring. Emerging AI-enabled and cloud-based environments will require life cycle-based governance, explainable, traceability and human oversight.